Tags

Type your tag names separated by a space and hit enter

Famotidine: effective treatment of Zollinger-Ellison syndrome.
J Clin Gastroenterol. 1987; 9 Suppl 2:23-5.JC

Abstract

The ability of famotidine to control gastric acid hypersecretion in 32 patients with Zollinger-Ellison syndrome was compared to that of cimetidine or ranitidine. Equipotent doses of each drug were determined in nine patients and famotidine was nine times more potent than ranitidine and 32 times as potent as cimetidine. Famotidine had a 30% longer duration of action than either ranitidine or cimetidine. The 32 patients were treated with famotidine for a mean follow-up of 10.5 months. No hematologic, biochemical, or clinical toxicity occurred. Famotidine appears to be the histamine H2-receptor antagonist of choice in the treatment of Zollinger-Ellison syndrome.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Controlled Clinical Trial
Journal Article

Language

eng

PubMed ID

2887615

Citation

Howard, J M., et al. "Famotidine: Effective Treatment of Zollinger-Ellison Syndrome." Journal of Clinical Gastroenterology, vol. 9 Suppl 2, 1987, pp. 23-5.
Howard JM, Vinayek R, Maton PN, et al. Famotidine: effective treatment of Zollinger-Ellison syndrome. J Clin Gastroenterol. 1987;9 Suppl 2:23-5.
Howard, J. M., Vinayek, R., Maton, P. N., Wank, S. A., Gardner, J. D., & Jensen, R. T. (1987). Famotidine: effective treatment of Zollinger-Ellison syndrome. Journal of Clinical Gastroenterology, 9 Suppl 2, 23-5.
Howard JM, et al. Famotidine: Effective Treatment of Zollinger-Ellison Syndrome. J Clin Gastroenterol. 1987;9 Suppl 2:23-5. PubMed PMID: 2887615.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Famotidine: effective treatment of Zollinger-Ellison syndrome. AU - Howard,J M, AU - Vinayek,R, AU - Maton,P N, AU - Wank,S A, AU - Gardner,J D, AU - Jensen,R T, PY - 1987/1/1/pubmed PY - 1987/1/1/medline PY - 1987/1/1/entrez SP - 23 EP - 5 JF - Journal of clinical gastroenterology JO - J Clin Gastroenterol VL - 9 Suppl 2 N2 - The ability of famotidine to control gastric acid hypersecretion in 32 patients with Zollinger-Ellison syndrome was compared to that of cimetidine or ranitidine. Equipotent doses of each drug were determined in nine patients and famotidine was nine times more potent than ranitidine and 32 times as potent as cimetidine. Famotidine had a 30% longer duration of action than either ranitidine or cimetidine. The 32 patients were treated with famotidine for a mean follow-up of 10.5 months. No hematologic, biochemical, or clinical toxicity occurred. Famotidine appears to be the histamine H2-receptor antagonist of choice in the treatment of Zollinger-Ellison syndrome. SN - 0192-0790 UR - https://www.unboundmedicine.com/medline/citation/2887615/Famotidine:_effective_treatment_of_Zollinger_Ellison_syndrome_ L2 - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=linkout&SEARCH=2887615.ui DB - PRIME DP - Unbound Medicine ER -